Scientists discover mechanism of resistance to vital leukaemia treatment, opening door to new therapies

March 19, 2013, King's College London
Scientists discover mechanism of resistance to vital leukaemia treatment, opening door to new therapies

(Medical Xpress)—Research published in the journal Cancer Cell has revealed the mechanism by which leukaemia cells develop resistance to the ATRA (All-Trans-Retinoic Acid) treatment, used to treat an aggressive form of cancer called acute promyelocytic leukemia (APL: a fast-growing cancer in which there are too many immature blood-forming cells in the blood and bone marrow). The research is by Professor Eric So, Department of Haematological Medicine at King's College London, and colleagues, and was funded by the charity Leukaemia & Lymphoma Research.

APL is a subtype of acute myelogenous leukaemia (AML) characterised by the presence of a specific leukaemia-inducing nuclear protein called PML-RARa, which activates abnormal gene expression programmes in the . APL represents five to eight per cent of AML in adults (approximately 200 new cases occur each year in the UK and 1500 new cases each year in the USA). The median age of diagnosis is approximately 40 years, which is considerably younger than the other subtypes of AML (70 years). Without proper medicine and treatment, APL is fatal.

The successful application of ATRA treatment for APL started in 1986 in Shanghai, China. It was soon widely adapted around the world. While ATRA alone induces a complete remission in the majority of the APL patients, patients will relapse and become resistant to the treatment. Recent refinements have improved results: ATRA is used in combination with low dose chemotherapy and more recently with Arsenic Trioxide, which have now led to long-term complete remissions in as high as 80 per cent of patients.

But while ATRA treatment revolutionised care for APL, and has been the paradigm of targeted therapy for leukaemia-inducing nuclear proteins, the underlying mechanisms remain largely unknown, and roughly 20 per cent of patients who enter into a complete remission will still relapse and become resistant to the treatment. Only half of these patients will be alive after three years. Also, while the success of ATRA treatment in APL sets the stage for targeted therapy of leukaemia-inducing nuclear proteins, retinoic acid (RA) treatment has so far been shown to be ineffective in treating other cancers. Thus cracking the mechanism of action of this drug is essential.

In this study, Dr So and colleagues discovered the accessory enzyme PHF8 as a critical molecular sensor for mediating ATRA treatment response in APL. Using a molecular biology approach, his group identified that PHF8 specifically bound to PML-RARa in response to ATRA treatment, and this interaction was required for eradication of APL . ATRA-resistant APL cells also had reduced level of PHF8. By activating the activities of PHF8 using a molecular biology approach or chemical intervention, it could resurrect ATRA-sensitivity to treatment resistant APL cells in both mouse models and human cell lines derived from APL patients. In contrast, its suppression led to ATRA-.

In addition, they discovered that PHF8 is regulated by a specific type of protein modification, called phosphorylation. As a proof of principle experiment, Dr. So and colleagues demonstrated that pharmacological enhancement of PHF8 phosphorylation was able to sensitise treatment resistant APL cells to ATRA both in cell culture and in the whole animals. Dr So said: 'These results reveal a critical function of this class of accessory enzymes in mediating treatment and open up a novel avenue for overcoming treatment resistance in APL. The next stage of the research will be to identify the key molecules that affect the activity of PHF8, and to develop specific drugs that will promote the functions of PHF8 in mediating response.'

In this study, a generic inhibitor (okadaic acid) that promotes PHF8 phosphorylation has shown an encouraging efficacy in inducing ATRA response in resistant APL cells. 'It is quite possible that specific and more effective drugs can be developed if we can improve the specificity of some of these generic inhibitors in the coming years,' said Dr So. 'In parallel, we are also trying to identify the key and tractable PHF8 regulators for the development of a new class of small molecule inhibitors effectively targeting the activity of PHF8.'

Explore further: Scientists find genetic key to why some cancer patients don't respond to treatment

Related Stories

Scientists find genetic key to why some cancer patients don't respond to treatment

January 5, 2012
(Medical Xpress) -- Researchers from Newcastle University have identified a gene variation carried by 20% of the population which can significantly affect how patients with a rare type of blood cancer will respond to treatment.

ATRA and arsenic trioxide versus ATRA and idarubicin for newly diagnosed, non high-risk acute promyelocytic

December 9, 2012
New research demonstrates the efficacy of the first curative treatment for acute promyelocytic leukemia (APL) that does not include chemotherapy, marking an important step toward front-line use of targeted therapies for acute ...

Tranylcypromine antidepressant shows promise as cancer treatment

March 11, 2012
A retinoid called all-trans retinoic acid (ATRA), which is a vitamin A-derivative, is already used successfully to treat a rare sub-type of acute myeloid leukemia (AML), however this drug has not been effective for the more ...

Link between prostate cancer and vitamin A may lead to improved treatment

September 5, 2012
(Medical Xpress)—Cancer scientists at the University of York have shown a link between prostate cancer and vitamin A for the first time.

Recommended for you

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.